Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway

Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases, including glaucoma. EPO-R76E retains the neuroprotective effects of EPO but diminishes the effects on hematocrit. Treatment with EPO-R76E in a glaucoma model increases expression of antioxidant proteins and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Naguib, Sarah, DeJulius, Carlisle R., Backstrom, Jon R., Haider, Ameer A., Ang, John M., Boal, Andrew M., Calkins, David J., Duvall, Craig L., Rex, Tonia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045745/
https://www.ncbi.nlm.nih.gov/pubmed/36978804
http://dx.doi.org/10.3390/antiox12030556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045745/
https://www.ncbi.nlm.nih.gov/pubmed/36978804
http://dx.doi.org/10.3390/antiox12030556

Ejemplares similares